Vomiting
Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns
Amgen; MariTide; Phase 3; obesity treatment; dose escalation; vomiting; adverse events; clinical trial; GLP-1 receptor; GIP receptor
Roche’s Obesity Pill Candidate Faces Safety Concerns Amid Promising Efficacy Results
Roche, Obesity Pill, Safety Concerns, Efficacy Data, CT-996, Side Effects, Nausea, Vomiting, Gastrointestinal Issues